These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 10805344)

  • 1. In vitro glatiramer acetate treatment of brain endothelium does not reduce adhesion phenomena.
    Dufour A; Corsini E; Gelati M; Massa G; Tarcic N; Salmaggi A
    Ann Neurol; 2000 May; 47(5):680-2. PubMed ID: 10805344
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of glatiramer acetate (Copaxone) given orally in human patients: interleukin-10 production during a phase 1 trial.
    de Seze J; Edan G; Labalette M; Dessaint JP; Vermersch P
    Ann Neurol; 2000 May; 47(5):686. PubMed ID: 10805349
    [No Abstract]   [Full Text] [Related]  

  • 3. Glatiramer: a second look. With longer follow-up: still no proven benefit in multiple sclerosis.
    Prescrire Int; 2009 Dec; 18(104):252. PubMed ID: 20025092
    [No Abstract]   [Full Text] [Related]  

  • 4. Glatiramer acetate for relapsing multiple sclerosis.
    Med Lett Drugs Ther; 1997 Jul; 39(1004):61-2. PubMed ID: 9217693
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study.
    Blanco Y; Moral EA; Costa M; Gómez-Choco M; Torres-Peraza JF; Alonso-Magdalena L; Alberch J; Jaraquemada D; Arbizu T; Graus F; Saiz A
    Neurosci Lett; 2006 Oct; 406(3):270-5. PubMed ID: 16934924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical and MRI effects of Glatirameracetate].
    Nervenarzt; 1999 Aug; 70(8 Suppl):1-8. PubMed ID: 10511871
    [No Abstract]   [Full Text] [Related]  

  • 7. Glatiramer acetate in multiple sclerosis.
    Mezzapesa DM; Rovaris M; Filippi M
    Expert Rev Neurother; 2005 Jul; 5(4):451-8. PubMed ID: 16026228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis.
    Kornek B; Bernert G; Balassy C; Geldner J; Prayer D; Feucht M
    Neuropediatrics; 2003 Jun; 34(3):120-6. PubMed ID: 12910434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glatiramer acetate: evidence for a dual mechanism of action.
    Blanchette F; Neuhaus O
    J Neurol; 2008 Mar; 255 Suppl 1():26-36. PubMed ID: 18317674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon beta-1a downregulates TNFalpha-induced intercellular adhesion molecule 1 expression on brain microvascular endothelial cells through a tyrosine kinase-dependent pathway.
    Defazio G; Livrea P; Giorelli M; Martino D; Roselli F; Ricchiuti F; Trojano M
    Brain Res; 2000 Oct; 881(2):227-30. PubMed ID: 11036165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS.
    Pöllmann W; Erasmus LP; Feneberg W; Straube A
    Neurology; 2006 Jan; 66(2):275-7. PubMed ID: 16434675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis].
    Correale J; Cristiano E
    Medicina (B Aires); 2001; 61(4):470-80. PubMed ID: 11563177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate.
    Neuhaus O; Stüve O; Archelos JJ; Hartung HP
    J Neurol Sci; 2005 Jun; 233(1-2):173-7. PubMed ID: 15949504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory potential and migratory capacities across human brain endothelial cells of distinct glatiramer acetate-reactive T cells generated in treated multiple sclerosis patients.
    Kim HJ; Biernacki K; Prat A; Antel JP; Bar-Or A
    Clin Immunol; 2004 Apr; 111(1):38-46. PubMed ID: 15093550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.
    Johnson KP; Due DL
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):205-14. PubMed ID: 19527092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glatiramer acetate: mechanisms of action in multiple sclerosis.
    Schrempf W; Ziemssen T
    Autoimmun Rev; 2007 Aug; 6(7):469-75. PubMed ID: 17643935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Multiple sclerosis: immunomodulators brake the appearance of "black holes"].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():110. PubMed ID: 14579503
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis.
    Rudick RA
    J Neuroimaging; 2004 Jul; 14(3 Suppl):54S-64S. PubMed ID: 15228760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.